A5085036155- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Lymphoma Diagnosis and Treatment
- Platelet Disorders and Treatments
- Chronic Lymphocytic Leukemia Research
- Acute Myeloid Leukemia Research
- Bone and Joint Diseases
- Eosinophilic Disorders and Syndromes
- Heparin-Induced Thrombocytopenia and Thrombosis
- CNS Lymphoma Diagnosis and Treatment
- Autoimmune and Inflammatory Disorders Research
- Viral-associated cancers and disorders
- Kruppel-like factors research
- Multiple Myeloma Research and Treatments
- Gastric Cancer Management and Outcomes
- Venous Thromboembolism Diagnosis and Management
- Hemoglobinopathies and Related Disorders
- Blood groups and transfusion
- Autoimmune Bullous Skin Diseases
University of Bologna
2021-2025
Istituto di Ematologia di Bologna
2021-2024
Abstract Background Patients with cytopenic myelofibrosis (MF) have more limited therapeutic options and poorer prognoses compared patients the myeloproliferative phenotype. Aims Methods Prognostic correlates of phenotype were explored in 886 ruxolitinib‐treated primary/secondary MF (PMF/SMF) included RUX‐MF retrospective study. Cytopenia was defined as: leukocyte count <4 × 10 9 /L and/or hemoglobin <11/<10 g/dL (males/females) platelets <100 /L. Results Overall, 407 (45.9%) had...
Abstract Immune checkpoint inhibitors (CPIs) emerged as an effective and safe therapeutic option for patients with relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL). However, many lose their response to CPIs. To improve outcomes in this setting, two strategies can be considered: salvage chemotherapy (CHT) those unsatisfactory response, autologous stem-cell transplantation (auto-SCT) a consolidation at least partial (PR). We analyzed retrospectively the effectiveness terms of rate...
PURPOSE Ruxolitinib improves splenomegaly and disease-related symptoms in most patients with myelofibrosis (MF), it has been associated a survival benefit higher-risk splenomegaly. Spleen volume reduction ruxolitinib-treated patients; however, its use as surrogate is limited. We hypothesized that an anti-inflammatory response to ruxolitinib would correlate improved patient outcomes. METHODS interrogated serum albumin, acute phase reactant marker of nutritional status 590 MF analyzed...
In polycythemia vera (PV), the prognostic relevance of an ELN-defined complete response (CR) to hydroxyurea (HU), predictors response, and patients’ triggers for switching ruxolitinib are uncertain. a real-world analysis, we evaluated their impact on clinical outcomes CR HU, correlations between partial or no (PR/NR) patient ruxolitinib. Among 563 PV patients receiving HU ≥12 months, 166 (29.5%) achieved CR, 264 PR, 133 NR. multivariate absence splenomegaly (p = 0.03), pruritus 0.002),...
ABSTRACT First‐line therapy for patients with extranodal marginal zone lymphoma (EMZL) is not well established, except eradication Helicobacter pylori in early gastric MZL. Various regimens, example, locoregional treatment and systemic chemo‐immunotherapy, can be used depending on the site stage of disease. Single‐agent rituximab a useful approach setting localized, low‐intermediate risk EMZL. The aim our research was to analyze effectiveness safety single‐agent (375 mg/m 2 once weekly 4...
Fostamatinib is a SYK-inhibitor drug recently approved by the FDA and EMA for treating chronic immune thrombocytopenia. This induces response in about 40% of patients has good toxicity profile. It known that discontinuing thrombopoietin receptor agonists (TRAs) with maintenance sustained off therapy possible. On fostamatinib, we do not yet have such information. In this case report, describe story woman multirefractory thrombocytopenia (steroids, splenectomy, rituximab, both available TRAs)....
Several infections and vaccinations can provoke immune thrombocytopenia (ITP) onset or relapse. Information on ITP epidemiology management during the Covid-19 pandemic is scarce. In a large monocenter cohort, we assessed incidence risk factors for: 1) onset/relapse after Covid19 vaccination/infection; 2) infection.Information date/type of anti-Covid-19 vaccine, platelet count before within 30 days from date/grade was collected via phone call hematological visits. relapse defined as drop in...
Topic: 16. Myeloproliferative neoplasms - Clinical Background: RUX was the first JAK1/2 inhibitor approved for MF patients (pts), with 70% of pts discontinuing within 5 yrs. Recently, Response to After 6 Months (RR6) model developed early identification RUX-treated worse overall survival (OS). Aims: To investigate predictors Rux discontinuation and death while on therapy. Methods: The “RUX-MF” retrospective study includes 889 receiving in real-life. This analysis focused 410 including: 172...